DOCSLIB.ORG

Management of Retained Placenta

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Management of Retained Placenta WAHT-OBS-091 It is the responsibility of every individual to check that this is the latest version/copy of this document MANAGEMENT OF RETAINED PLACENTA This guidance does not override the individual responsibility of health professionals to make appropriate decision according to the circumstances of the individual patient in consultation with the patient and /or carer. Health care professionals must be prepared to justify any deviation from this guidance. INTRODUCTION This guideline should be used in conjunction with WAHT-OBS-030 (MD13) Management of Post Partum Haemorrhage. Retained placenta is diagnosed when the woman is unable to deliver the placenta by 30 minutes following active management of third stage and by one hour after physiological third stage of labour. Retained Placenta complicates 1-2% of all deliveries and this incidence is much higher in preterm deliveries. In many cases retained placenta is associated with postpartum haemorrhage and can result in significant maternal morbidity and mortality. THIS GUIDELINE IS FOR USE BY THE FOLLOWING STAFF GROUPS : Midwives and Obstetricians Lead Clinician(s) Lakshmi Consultant Obstetrician Extended version approved by representatives of the 24 June 2010 Obstetric Guidelines Group on: This version approved at Obstetric Governance 20th February 2015 Committee on: This guideline should not be used after end of: 20th February 2017 Key amendments to this guideline Date Amendment By: 24 June 2010 Extended for a further period without amendment. Miss R Imtiaz 29.07.2012 Reminder that persistent steady blood loss can result Miss R Duckett in an underestimate of a significant PPH January 2015 Reviewed by microbiologist dept agreed to keep Dr Dyas antibiotic cover Management of retained placenta WAHT-OBS-091 Page 1 of 9 Version 3.2 WAHT-OBS-091 It is the responsibility of every individual to check that this is the latest version/copy of this document MANAGEMENT OF RETAINED PLACENTA INTRODUCTION Retained placenta is diagnosed when the woman is unable to deliver the placenta by 30 minutes following active management of third stage and by one hour after physiological third stage of labour. Retained Placenta complicates 1-2% of all deliveries and this incidence is much higher in preterm deliveries. In many cases retained placenta is associated with postpartum haemorrhage and can result in significant maternal morbidity and mortality. The use of prophylactic oxytocics reduces the length of the third stage compared to physiological management, but there is no difference in the number who requires manual removal. There is a greater incidence of retained placenta when ergometrine is used compared to oxytocin 5 or 10 units alone. Types of Retained Placenta 1. Trapped placenta - is when the placenta is detached/ separated but merely trapped behind a closed cervix. 2. Adherent Placenta - is when the placenta is adherent to the uterine wall (associated with previous caesarean section, uterine surgery). Patients with prolonged third stage may have different clinical reasons for retained placenta and therefore may require different management. MANAGEMENT OF RETAINED PLACENTA The most important factor to determine management plan is presence or absence of active bleeding. In the presence of active bleeding Insert 16G IV cannula and obtain bloods for FBC and Group & save. Monitor and record Pulse and Blood pressure Inform Obstetric Registrar Inform on-call anaesthetist Insert urinary Foley’s catheter Commence and continue oxytocin infusion 40 u/l 250mls/hour Perform vaginal examination to ascertain whether the placenta is already separate in which case it can be removed. Record blood loss and request cross match blood if clinically indicated. (Remember that persistent steady blood loss can result in an underestimate of a significant PPH). Urgently prepare and transfer patient to theatre for manual removal of placenta (MRP) NB: There is no evidence that repeated bolus doses of oxytocics before placental delivery, assist in the delivery of adherent placenta. Repeated doses of uterotonics may result in contraction of uterine cervix resulting in difficult manual removal. Management of retained placenta WAHT-OBS-091 Page 2 of 9 Version 3.2 WAHT-OBS-091 It is the responsibility of every individual to check that this is the latest version/copy of this document Home Delivery: If the placenta is retained after a home delivery, the woman should be transferred to hospital for further management and manual removal. If there is associated active bleeding usual protocol for PPH after home birth should be followed. Misoprostol 800microgram can be inserted PR while awaiting transfer to the hospital. Misoprostol is effective in the treatment of postpartum haemorrhage, but its uterotonic effect is slower in onset than the oxytocin (probably 30 to 60 minutes) and therefore it is likely to prevent later uterine relaxation than have much effect on the acute loss. It is especially useful in cases where oxytocin infusion is difficult to commence due to poor venous access. Misoprostol can cause pyrexia, nausea and vomiting and it is contraindicated in asthmatic and cardiac patients. Manual Removal of Placenta ( MRP) MRP should be performed by an experienced obstetrician. It should be performed in theatre under regional / general anaesthetic. Place gloved hand into uterus under aseptic technique with other hand on fundus to control it. Follow umbilical cord until you find lower edge of placenta. Gently push the hand between the placenta and the body of the uterus and ease placenta away with a sawing action (N.B. in cases of placenta accreta the placenta will not detach easily and use of excess force can result in life-threatening haemorrhage which may require hysterectomy) If part/ total of the placenta is morbidly adherent and cannot be separated leave it insitu and inform the obstetric consultant on-call who should attend and manage accordingly (See PPH guidelines WAHT-OBS-030). When fully detached, explore the uterine cavity for damage and other pieces of placenta or membranes. Massage fundus with one hand whilst extracting placenta and membranes with hand in uterine cavity. Examine the placenta to be sure that it is complete. Inject oxytocin 5 units IV and continue oxytocin infusion (as mentioned above). Give single dose IV antibiotics – 1.2g co-amoxiclav unless otherwise indicated. If patient penicillin allergic give cefuroxime 1.5g IV and metronidazole 500mg IV. If patient known to be severely penicillin allergic i.e. anaphylaxis discuss with consultant microbiologist. Debrief the patient. Complications of Manual Removal of Placenta o PPH (See guideline WAHT-OBS-030) o Infection/ puerperal sepsis (Maintain aseptic technique for MRP and give antibiotics.) o Perforation of uterus (experienced obstetrician to perform MRP and explore the uterine cavity at the end of procedure.) o Inverted uterus ( See guideline WAHT-OBS-026) Management of retained placenta WAHT-OBS-091 Page 3 of 9 Version 3.2 WAHT-OBS-091 It is the responsibility of every individual to check that this is the latest version/copy of this document In the absence of active bleeding Try breast feeding, nipple stimulation, emptying bladder and change of position – encourage upright position. Check pulse and blood pressure half hourly Do not leave unattended Regularly check for PV loss and any signs of placental separation Catheterise the bladder if not emptied recently Insert 16G IV cannula and obtain bloods for FBC and Group & save as risk of PPH. Inform Obstetric Registrar If experienced in ultrasound scanning on-call obstetrician may perform USS to distinguish between a trapped placenta and an adherent placenta. Trapped Placenta can be treated by obtaining acute uterine relaxation - giving the woman glycerol trinitrate (GTN) - two 400mg puffs sublingually or a single dose of Terbutaline 250 microgram subcutaneously. Followed by delivery of the placenta by controlled cord traction NB: Beware of hypotension and PPH and administer prophylactic oxytocin infusion 40 u/l 250mls/hour afterwards. Adherent Placenta. Effective treatment of adherent placenta is based on stimulating contractions of underlying myometrium, to induce separation of placenta. This may be achieved by injection of 30iu oxytocin in 20 ml normal saline down the umbilical cord by the Pipingas method (see below) Followed by delivery of the placenta by controlled cord traction If this is unsuccessful then manual removal (MRP) should be carried out in theatre with adequate analgesia and antibiotic cover as explained above. NB: The administration of prophylactic oxytocin before placental delivery does not reduce the incidence of postpartum hemorrhage or third-stage duration, when compared with giving oxytocin after placental delivery. Early administration, however, does not increase the incidence of retained placenta (Remember that persistent steady blood loss can result in an underestimate of a significant PPH). The Pipingas Technique Recut the cord to achieve a clean end Pass a size 10g nasogastric tube along the umbilical vein until resistance is felt Withdraw to the tube by 5cm to allow for any divisions of the vein prior to its insertion in the placenta Dilute 30 iu oxytocin in 20 ml of normal saline and inject directly down the nasogastric tube in the umbilical vein and then wait 5 minutes prior to trying controlled cord traction. The placenta can then be delivered by controlled cord traction Management of retained placenta WAHT-OBS-091 Page 4 of 9 Version 3.2 WAHT-OBS-091 It is the responsibility of every individual to check that this is the latest version/copy of this document MONITORING TOOL How will monitoring be carried out? Clinical Audit Who will monitor compliance with the guideline? Obstetric Governance Committee STANDARDS % CLINICAL EXCEPTIONS All placentas should be delivered by 3 hours 100% Patient choice REFERENCES Weeks A. (2005) The Retained Placenta in Progress in Obstetrics and Gynaecology 16, Chapter 9. Edited By John Studd. Churchill Livingstone. London Am J Obstet Gynecol. 2001 Oct;185(4):873-7 Jackson KW Jr et al High Risk Pregnancy.
Load more

Recommended publications
  • Retained Placenta and Postpartum Haemorrhage
    Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1077 Retained Placenta and Postpartum Haemorrhage JOHANNA BELACHEW ACTA UNIVERSITATIS UPSALIENSIS ISSN 1651-6206 ISBN 978-91-554-9182-6 UPPSALA urn:nbn:se:uu:diva-246185 2015 Dissertation presented at Uppsala University to be publicly examined in Rosénsalen, Ing 95/96, Akademiska sjukhuset, Uppsala, Thursday, 23 April 2015 at 13:15 for the degree of Doctor of Philosophy (Faculty of Medicine). The examination will be conducted in Swedish. Faculty examiner: Professor Kjell Å Salvesen (Lunds Universitet). Abstract Belachew, J. 2015. Retained Placenta and Postpartum Haemorrhage. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 1077. 59 pp. Uppsala: Acta Universitatis Upsaliensis. ISBN 978-91-554-9182-6. The aim was to explore the possibility to diagnose retained placental tissue and other placental complications with 3D ultrasound and to investigate the impact of previous caesarean section on placentation in forthcoming pregnancies. 3D ultrasound was used to measure the volumes of the uterine body and cavity in 50 women with uncomplicated deliveries throughout the postpartum period. These volumes were then used as reference, to diagnose retained placental tissue in 25 women with secondary postpartum haemorrhage. All but three of the 25 women had retained placental tissue confirmed at histopathology. The volume of the uterine cavity in women with retained placental tissue was larger than the reference in most cases, but even cavities with no retained placental tissue were enlarged (Studies I and II). Women with their first and second birth, recorded in the Swedish medical birth register, were studied in order to find an association between previous caesarean section and retained placenta.
    [Show full text]
  • Retained Placenta After Vaginal Birth - Uptodate
    2019/3/17 Retained placenta after vaginal birth - UpToDate Official reprint from UpToDate® www.uptodate.com ©2019 UpToDate, Inc. and/or its affiliates. All Rights Reserved. Retained placenta after vaginal birth Author: Andrew Weeks, MD, MRCOG Section Editor: Vincenzo Berghella, MD Deputy Editor: Vanessa A Barss, MD, FACOG All topics are updated as new evidence becomes available and our peer review process is complete. Literature review current through: Feb 2019. | This topic last updated: Dec 12, 2018. INTRODUCTION The third stage of labor is the interval from delivery of the infant to expulsion of the placenta. Delayed separation and expulsion of the placenta is a potentially life-threatening event because it interferes with normal postpartum contraction of the uterus, which can lead to hemorrhage. This topic will discuss the diagnosis and management of a retained placenta after vaginal birth. Management of retained products of conception after a miscarriage or pregnancy termination is reviewed separately. (See "Retained products of conception".) DEFINITION Retained placenta can be defined as lack of expulsion of the placenta within 30 minutes of delivery of the infant [1,2]. This is a reasonable definition in the third trimester when the third stage of labor is actively managed (ie, administration of a uterotonic agent before delivery of the placenta, controlled cord traction) because 98 percent of placentas are expelled by 30 minutes (figure 1) in this setting [3]. Physiological management of the third stage (ie, delivery of the placenta without the use of uterotonic agents or cord traction) increases the frequency of retained placenta: only 80 percent of placentas are expelled by 30 minutes (figure 1) and it takes about 60 minutes before 98 percent of placentas are expelled.
    [Show full text]
  • WHO Recommendations for the Prevention and Treatment of Postpartum Haemorrhage
    WHO recommendations for the prevention and treatment of postpartum haemorrhage For more information, please contact: Department of Reproductive Health and Research World Health Organization Avenue Appia 20, CH-1211 Geneva 27 Switzerland Fax: +41 22 791 4171 E-mail: [email protected] www.who.int/reproductivehealth Maternal, Newborn, Child and Adolescent Health E-mail: [email protected] www.who.int/maternal_child_adolescent WHO recommendations for the prevention and treatment of postpartum haemorrhage WHO Library Cataloguing-in-Publication Data WHO recommendations for the prevention and treatment of postpartum haemorrhage. 1.Postpartum hemorrhage – prevention and control. 2.Postpartum hemorrhage – therapy. 3.Obstetric labor complications. 4.Guideline. I.World Health Organization. ISBN 978 92 4 154850 2 (NLM classification: WQ 330) © World Health Organization 2012 All rights reserved. Publications of the World Health Organization are available on the WHO web site (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncom- mercial distribution – should be addressed to WHO Press through the WHO web site (http://www.who.int/ about/licensing/copyright_form/en/index.html). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries.
    [Show full text]
  • Postpartum Hemorrhage: Prevention and Treatment ANN EVENSEN, MD, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin JANICE M
    This is an updated version of the article that appeared in print. Postpartum Hemorrhage: Prevention and Treatment ANN EVENSEN, MD, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin JANICE M. ANDERSON, MD, Forbes Family Medicine Residency Program, Pittsburgh, Pennsylvania PATRICIA FONTAINE, MD, MS, HealthPartners Institute for Education and Research, Bloomington, Minnesota Postpartum hemorrhage is common and can occur in patients without risk factors for hemorrhage. Active man- agement of the third stage of labor should be used routinely to reduce its incidence. Use of oxytocin after delivery of the anterior shoulder is the most important and effective component of this practice. Oxytocin is more effective than misoprostol for prevention and treatment of uterine atony and has fewer adverse effects. Routine episiotomy should be avoided to decrease blood loss and the risk of anal laceration. Appropriate management of postpartum hemorrhage requires prompt diagnosis and treatment. The Four T’s mnemonic can be used to identify and address the four most common causes of postpartum hemorrhage (uterine atony [Tone]; laceration, hematoma, inversion, rupture [Trauma]; retained tissue or invasive placenta [Tissue]; and coagulopathy [Thrombin]). Rapid team-based care minimizes morbidity and mortality associated with postpartum hemorrhage, regardless of cause. Massive trans- fusion protocols allow for rapid and appropriate response to hemorrhages exceeding 1,500 mL of blood loss. The National Partnership for Maternal Safety has developed an obstetric hemorrhage consensus bundle of 13 patient- and systems-level recommendations to reduce morbidity and mortality from postpartum hemorrhage. (Am Fam Physi- cian. 2017;95(7):442-449. Copyright © 2017 American Academy of Family Physicians.) More online pproximately 3% to 5% of obstet- Prevention at http://www.
    [Show full text]
  • The Retained Placenta
    The Retained Placenta Andrew D Weeks Visiting Lecturer, Makerere University, Faculty of Medicine, Department of Obstetrics and Gynaecology Abstract The retained placenta is a significant cause of maternal mortality and morbiditythroughout the developing world. It complicates 2% of all deliveries and has a case mortality rate of nearly 10% in rural areas. Ultrasound ~tudies have provided fresh insights into the mechanism of the third stage of labour and the aetiology of the retained placenta. Following delivery of the baby, the retro-placental myometrium is initially relaxed. It is only when it contracts that the placenta shears away from the placental bed and is detached. This leads to its spontaneous expulsion. Retained placenta occurs when the retro-placental myometrium fails to contract. There is evidence that this may also occur during labour leading to dysfunctional labour. It is likely that this Is caused by the persistence of one of the placental inhibitory factors that are normally reduced prior to the onset of labour, possibly progesterone or nitric oxide. Presently, the only effective treatment is manual removal of placenta (MROP) under anaesthetic. This needs to be carried out within a few hours of delivery to avoid haemorrhage. For women in rural Africa, facilities for MROPare scarce, leading to high mortality rates. Injection of oxytocin Into the umbilical vein has been suggested as an alternative. This method relies on the injected oxytocin passing through the placenta to contract the retro-p lace ntal myometrium and cause its detachment. Despite several placebo controlled trials of this technique, no firm conclusion have been reached regarding its efficacy.
    [Show full text]
  • Clinical Perinatal/Neonatal Case Presentation ⅢⅢⅢⅢⅢⅢⅢⅢⅢⅢⅢⅢⅢⅢ Placenta Accreta and Methotrexate Therapy: Three Case Reports
    Clinical Perinatal/Neonatal Case Presentation ⅢⅢⅢⅢⅢⅢⅢⅢⅢⅢⅢⅢⅢⅢ Placenta Accreta and Methotrexate Therapy: Three Case Reports George M. Mussalli, MD the treatment of placenta accreta. The known effect of methotrexate Jelpa Shah, MD on reducing placental vascularity, resulting in placental necrosis, and David J. Berck, MD the considerable morbidity and mortality of surgical management of Andrew Elimian, MD placenta accreta, provided the justification for attempting medical Nergesh Tejani, MD treatment of the retained placenta. A MEDLINE search from 1966 to Frank A. Manning, MD 1999 (keywords: placenta accreta, methotrexate, retained placenta, medical treatment) yielded only six other reports of methotrexate management of accreta.4–9 Of the two reports representing an Ameri- Placenta accreta is a complication that is rising in incidence. The can experience,6,7 the authors offer contradictory conclusions regard- reported experience of methotrexate treatment in the conservative ing conservative management and methotrexate treatment for re- management of placenta accreta is scant. Three cases of placenta accreta tained placenta accreta. One case of placenta accreta, one case of managed with methotrexate are presented. placenta percreta, and one case of placenta percreta with bladder Case 1: A woman had an antenatal diagnosis of placenta percreta. A involvement, all managed with methotrexate, are presented here. All successful manual placental removal occurred on post-cesarean day 16. patients were offered and agreed to methotrexate courses as adjunctive Case 2: A woman had retention of a placenta accreta after a term vaginal treatment to conservative management on a case by case basis by the delivery. Successful dilation and curettage were performed on postpar- admitting attending perinatologist.
    [Show full text]
  • WHO Guidelines for the Management of Postpartum Haemorrhage and Retained Placenta
    WHO guidelines for the management of postpartum haemorrhage and retained placenta WHO guidelines for the management of postpartum haemorrhage and retained placenta WHO Library Cataloguing-in-Publication Data: WHO guidelines for the management of postpartum haemorrhage and retained placenta. 1.Placenta, Retained - therapy. 2.Postpartum hemorrhage - diagnosis. 3.Postpartum hemorrhage - therapy. 4.Obstetric labor complications. 5.Guidelines. I.World Health Organization. ISBN 978 92 4 159851 4 (NLM classification: WQ 330) © World Health Organization 2009 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • The Placenta Accreta Spectrum: Pathophysiology and Evidence-Based Anatomy for Prenatal Ultrasound Imaging
    The Placenta Accreta Spectrum: Pathophysiology and Evidence-based Anatomy for Prenatal Ultrasound Imaging Eric Jauniaux1, Sally Collins2, Graham J Burton3 1. EGA Institute for Women’s Health, Faculty of Population Health Sciences, University College LonDon (UCL), LonDon, UK. 2. NuffielD Department of Obstetrics & Gynaecology, University of Oxford, anD the Fetal MeDicine Unit, John RaDcliffe Hospital, Oxford, UK 3. The Centre for Trophoblast Research, Department of Physiology, Development anD Neuroscience, University of CambriDge, CambriDge, UniteD KingDom. [email protected]. The authors report no conflict of interest No funDing Was obtaineD for this stuDy. Corresponding author: Professor Eric Jauniaux, Academic Department of Obstetrics and Gynaecology, Institute for Women’s Health, University College London, 86-96 Chenies Mews, London WC1E 6HX, UK. Telephone numbers: +44/207/3908113 Fax: +44/207/3908115 E-mail: [email protected] Word count: . (Abstract Word count 348) Short title: Pathophysiology anD ultrasounD imaging of placenta accreta spectrum Condensation: The pathophysiological basis of ultrasounD signs in placenta accreta is seconDary to permanent Damage of the uterine Wall anD invasion of the Deep uterine circulation. 1 Abstract The placenta accreta spectrum (PAS) is a complex obstetric complication associateD With a high maternal morbiDity. It is a relatively neW Disorder of placentation, and is the consequence of Damage to the enDometrium-myometrial interface of the uterine Wall. When first DescribeD 80 years ago, it mainly occurreD after manual removal of the placenta, uterine curettage or enDometritis. Superficial Damage leaDs primarily to an abnormally aDherent placenta, and is DiagnoseD as the complete or partial absence of the DeciDua on histology.
    [Show full text]
  • INTRODUCTION the Incidence of Retained Placenta Varies Greatly
    AN APPRAISAL OF RETAINED PLACENTAE IN IBADAN: A FIVE YEAR REVIEW G.O. Obajimi, A.O. Roberts, C.O. Aimakhu, F.A. Bello, and O. Olayemi Department of Obstetrics and Gynaecology, University of Ibadan, Nigeria. Correspondence: ABSTRACT Dr. G.O. Obajimi Objectives: To determine the frequency of retained placenta at Dept. of Obstetrics and Gynaecology, the University College Hospital Ibadan (UCH). and to describe University College Hospital, the socio-demographic characteristics of the patients and examine Ibadan. the risk factors predisposing to retained placenta. Methods: This is a descriptive study covering a period of 5 years from January 1st 2002 to December 31st 2006. During the study period, 4980 deliveries took place at the University College Hospital, Ibadan and 106 cases of retained placenta were managed making the incidence 2.13 per cent of all births. Results: During the five year period, there were 106 patients with retained placenta; of these, 90 (84.9%) case notes were available for analysis. The mean age was 29.37 ± 4.99 years. First and second Para accounted for 52 per cent of the patients. Majority of the patient were unbooked for antenatal care in UCH with booked patients accounting for 27.8 per cent of the cases. The mean gestational age at delivery was 34.29 ± 6.02. Three patients presented to the hospital in shock of which 2 died on account of severe haemorrhagic shock. Fifty-eight patients (64.8%) presented with anaemia (packed cell volume less than 30 per cent) and 35 patients (38.8%) had blood transfusion ranging between 1-4 pints.
    [Show full text]
  • Implementing Active Management of the Third Stage of Labor (AMTSL)
    Reference manual Core Topic 3: Uterotonic drugs Key definitions Tonic or tetanic contractions: Continuous contractions with no relaxation. Uterotonics: Substances that stimulate uterine contractions or increase uterine tone. Uterotonics include: Oxytocin (the most commonly used uterotonic drug): Oxytocin is secreted naturally by the posterior pituitary during later pregnancy, labor, and when the baby breastfeeds. Synthetic forms of oxytocin can be found in products such as Pitocin® and Syntocinon®. In moderate doses, oxytocin produces slow, generalized contractions of the muscles of the uterus with full relaxation in between. High doses of oxytocin produce sustained tonic contractions that can be dangerous. Ergot-based compounds (another class of uterotonic drugs): Methergine® (methylergonovine maleate) and ergometrine (ergometrine maleate) are the ergot preparations used today. They cause tetanic (continuous) contractions of the uterus and may cause or exacerbate high blood pressure. Syntometrine (a combination of oxytocin and ergometrine maleate): Syntometrine has both the fast-acting quality of oxytocin and the tetanic contraction action of ergometrine. Prostaglandins (naturally occurring fatty acids found in the uterus, menstrual fluids, and amniotic fluid): Misoprostol, an E1 analog prostaglandin, is used for a range of obstetric and gynecologic purposes such as cervical ripening, induction of labor, prevention and treatment of PPH, and post-abortion care. Use of uterotonics Uterotonics act directly on the smooth muscle of the uterus and increase the tone, rate, and strength of rhythmic contractions. The body produces a natural uterotonic—the hormone oxytocin—that acts to stimulate uterine contractions at the start of labor and throughout the birth process. Drugs such as oxytocin, ergometrine, and misoprostol have strong uterotonic properties and are used to treat uterine atony and reduce the amount of blood lost after childbirth.
    [Show full text]
  • Predictors of Women's Physical Health Problems After Childbirth
    Journal of Psychosomatic Obstetrics & Gynecology, June 2005; 26(2): 115–125 Predictors of women’s physical health problems after childbirth DONNA ANSARA1,2, MARSHA M. COHEN1,2, RUTH GALLOP3, ROSE KUNG4,& BERIT SCHEI1,5 1Centre for Research in Women’s Health, University of Toronto and Sunnybrook and Women’s Health Sciences Centre, Toronto, Canada, 2Department of Health Policy, Management and Evaluation, University of Toronto, Toronto, Canada, 3Faculty of Nursing, University of Toronto, Toronto, Canada, 4Department of Obstetrics and Gynecology, Sunnybrook and Women’s Health Sciences Centre, University of Toronto, Toronto, Canada, and 5Department of Community Medicine and General Practice, the Norwegian University of Science and Technology, Trondheim, Norway (Received 21 August 2003; accepted 29 June 2004) Abstract The objectives of this study were to document the extent and the correlates of common physical health symptoms in women two months after childbirth. Of special interest was determining whether violence and depression histories increase the risk for experiencing these symptoms. Participants were recruited in six Toronto-area hospitals and were interviewed by telephone 8–10 weeks later. Two hundred of the 332 (60.2%) women who were approached completed the study. Most women (96%) reported at least one physical health symptom 2 months postnatally (Mean = 3.4, SD = 2.0). Stepwise logistic regression was conducted for each outcome. Antenatal depression was a significant predictor of excessive fatigue and bad headaches. Sick leave during pregnancy predicted postpartum backaches. Adult emotional abuse and household income were associated with bowel problems. Episiotomy, maternal complications, and planned pregnancy predicted perineal pain. Finally, being Canadian born and having an assisted vaginal delivery increased the risk for hemorrhoids while cesarean section decreased the risk.
    [Show full text]
  • Managing Complications in Pregnancy and Childbirth: a Guide for Midwives and Doctors
    Integrated Management Of Pregnancy And Childbirth Managing Complications in Pregnancy and Childbirth: A guide for midwives and doctors WHO UNFPA UNICEF World Bank Department of Reproductive Health and Research Integrated Management Of Pregnancy And Childbirth Managing Complications in Pregnancy and Childbirth: A guide for midwives and doctors Department of Reproductive Health and Research WHO Library Cataloguing-in-Publication Data Managing complications in pregnancy and childbirth: a guide for midwives and doctors. At head of title: Integrated Management of Pregnancy and Childbirth. 1.Pregnancy complications - diagnosis 2.Pregnancy complications - therapy 3.Labor, Obstetric 4.Delivery, Obstetric 5.Manuals I.World Health Organization. ISBN 92 4 154587 9 (NLM classification: WQ 240) © World Health Organization 2000, reprint 2007 All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: [email protected]). Requests for permission to reproduce or translate WHO publications—whether for sale or for noncommercial distribution—should be addressed to Publications, at the above address (fax: +41 22 791 4806; email: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned.
    [Show full text]